Live Feeds
● LIVE Updated 1h ago · 7 sources tracked

Drugmaker's Shares Triple on Leukemia Vaccine News

Sellas Life Sciences shares tripled following positive clinical trial results for an experimental blood cancer immunotherapy. The leukemia vaccine successfully passed a key trial, improving survival rates and reducing the risk of death in patients with acute myeloid leukemia. This development adds to a breakthrough year for cancer drugs and places the treatment among biotech industry highlights. Alongside the clinical milestone, the company announced the pricing of a one hundred fifty million dollar underwritten public offering.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (7)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Sellas Life Sciences shares tripled following news that its experimental blood cancer immunotherapy passed a key clinical trial and reduced the risk of death.
  • ✓ The vaccine improved survival in people with acute myeloid leukemia.
  • ✓ SELLAS Life Sciences announced the pricing of a one hundred fifty million dollar underwritten public offering.
🛡️ Source Corroboration: 7 independent reporting domains (90% confidence) ⏱ Read time: ~2 min

What changed

Sellas Life Sciences shares tripled in value following clinical trial data showing the experimental immunotherapy reduced the risk of death in blood cancer patients.

Live updates

  1. Drugmaker's Shares Triple on Leukemia Vaccine News

    Sellas Life Sciences shares tripled following positive clinical trial results for an experimental blood cancer immunotherapy. The leukemia vaccine successfully passed a key trial, improving survival rates and reducing the risk of death in patients with acute myeloid leukemia. This development adds to a breakthrough year for cancer drugs and places the treatment among biotech industry highlights. Alongside the clinical milestone, the company announced the pricing of a one hundred fifty million dollar underwritten public offering.

    Why it matters

    The positive data for the acute myeloid leukemia vaccine arrives during a strong period for cancer drug development. Immunotherapies targeting blood cancers draw significant attention from biotech investors seeking effective survival treatments. Financial maneuvers like public offerings often accompany major stock surges to capitalize on high market valuation and interest.

    What is confirmed

    • Sellas Life Sciences shares tripled following news that its experimental blood cancer immunotherapy passed a key clinical trial and reduced the risk of death.
    • The vaccine improved survival in people with acute myeloid leukemia.
    • SELLAS Life Sciences announced the pricing of a one hundred fifty million dollar underwritten public offering.

    Still unconfirmed

    • SLS joins MRNA and ANL in biotech's top three this year.

    What to watch next

    • Commercialization and regulatory updates regarding the leukemia vaccine
    • Market performance following the one hundred fifty million dollar public offering
    Sources used for this update (8)
    1. www.newser.com — 93-Year-Old Helps Police Catch Alleged Phone Scammer
    2. The Washington Post — Leukemia vaccine passes key trial, adding to breakthrough year for cancer drugs
    3. Memorial Sloan Kettering Cancer Center — Vaccine Improves Survival in People with Acute Myeloid Leukemia (AML)
    4. Yahoo Finance — SLS Joins MRNA And ANL In Biotech’s Top 3 This Year — Here’s How A Late-2025 Bet Could Grow 10x From Here
    5. Reuters — Sellas vaccine extends survival in blood cancer trial, shares surge
    6. STAT — Sellas’ experimental blood cancer immunotherapy reduced risk of death in clinical trial
    7. Newser — Drugmaker's Shares Triple on Leukemia Vaccine News
    8. Yahoo Finance — SELLAS Life Sciences Announces Pricing of $150.0 Million Underwritten Public Offering
    confidence 90%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community